Skip to main content
. Author manuscript; available in PMC: 2022 Jan 13.
Published in final edited form as: Mol Cancer Res. 2019 Mar 12;17(6):1365–1377. doi: 10.1158/1541-7786.MCR-18-0256

Figure 5. Impact of glutaminolysis inhibition on growth of MCL cells.

Figure 5.

(A) Growth inhibition of the depicted MCL cell lines in response to glutaminolysis inhibitor CB-839 as determined by viable cell count (top panel), BrdU uptake (middle panel), and MTT conversion index (bottom panel). (B) CB-839-mediated inhibition of cell cycle progression with cells exposed to the drug’s vehicle alone serving as control (CTR). (C) CB-839-mediated inhibition of cell division as determined by CSFE labeling pattern with cells exposed to the drug’s vehicle alone serving as control (CTR). Data were presented as mean±SEM.